Brevan Howard Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Brevan Howard Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,530	Closed	-$759K	–	1278
2024 Q2	$759K	Buy	+5,530	New	+$738K	0.01%	465
2023 Q2	–	Sell	-40,000	Closed	-$5.17M	–	204
2023 Q1	$5.17M	Hold	40,000	–	–	0.14%	45
2022 Q4	$5.25M	Buy	+40,000	New	+$5.17M	0.18%	30
2017 Q1	–	Sell	-249,000	Closed	-$22M	–	3
2016 Q4	$22M	Hold	249,000	–	–	65.06%	1
2016 Q3	$24M	Buy	+249,000	New	+$23.7M	2.03%	2

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Brevan Howard Capital Management's IBB Position: Q3 2024 in Review

Brevan Howard Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2024, closing a stake of 5,530 shares — an estimated $759K sold.

Brevan Howard Capital Management first reported a position in IBB in Q3 2016 and held it in 5 quarters. The position peaked at $24M in Q3 2016. 893 funds tracked by Wall St. Rank hold IBB as of Q3 2024.

Brevan Howard Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2024 after selling out during the quarter.
Brevan Howard Capital Management sold 5,530 iShares Biotechnology ETF shares in Q3 2024, an estimated $759K.
Brevan Howard Capital Management first reported a position in iShares Biotechnology ETF in Q3 2016 and held it in 5 quarters.
Brevan Howard Capital Management's iShares Biotechnology ETF position peaked at $24M in Q3 2016.
893 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2024.

Based on Brevan Howard Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.